Key Takeaways The S&P 500 added 0.1% on Tuesday, Jan. 14, as tame wholesale inflation data provided a positive signal ahead ...

Shares of Eli Lilly were taking a 6.9% hit toward a two-month low in recent trading, enough to make them the S&P 500's biggest decliner. The problem is that the drug giant provided fourth-quarter ...

All told, Lilly stock still gained 33% in 2024, outperforming the S&P 500 and Nasdaq Composite. Unfortunately, Lilly ...

Most U.S. stocks rose Tuesday following an encouraging update on inflation, though drops for Eli Lilly and other influential ...

S&P 500 edges higher, Nasdaq dips in choppy session as inflation data eyed 12:08 AM UTC Eli Lilly's stock tumbled 8% on Tuesday after it forecast fourth-quarter sales of weight-loss drug Zepbound ...

Bank of America Securities analyst Tim Anderson maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) today. The company’s ...

2024 was an interesting year for pharmaceutical powerhouse Eli Lilly (NYSE ... outperforming the S&P 500 and Nasdaq Composite. Unfortunately, Lilly investors haven't had much to celebrate so ...

Shares of pharmaceutical stock Eli Lilly are cratering after the company lowered its sales guidance for Q4. All told, Lilly stock still gained 33% in 2024, outperforming the S&P 500 and Nasdaq ...